Search

Corvus Pharmaceuticals Inc

Gesloten

13.23 2.64

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

12.85

Max

12.98

Belangrijke statistieken

By Trading Economics

Inkomsten

-4.3M

-18M

EPS

-0.19

Werknemers

37

EBITDA

-5.3M

-17M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+128.51% upside

Dividenden

By Acuity

Volgende Winsten

3 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

86M

1.2B

Vorige openingsprijs

10.59

Vorige sluitingsprijs

13.23

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 sep 2026, 23:51 UTC

Brazil's Business Confidence Index (ICEI) for September 2026 set to release on September 14, with cautious optimism amid persistent pessimism and geopolitical challenges.

13 sep 2026, 23:41 UTC

GBP/AUD shows notable strength in after-market trading, reaching a cumulative return peak of 0.17% since Friday's close, with no specific news identified.

13 sep 2026, 23:41 UTC

Correlated Moves

EUR/AUD is higher in after-market trading, diverging from the lower Nasdaq 100 Index amid heightened Fed interest rate hike expectations following a strong consumer price index report.

13 sep 2026, 23:31 UTC

China's House Price Index YoY release on September 15, 2026, is anticipated to reveal ongoing weakness in the housing sector amid cautious optimism from recent policy measures.

13 sep 2026, 23:31 UTC

U.S. Building Permits Forecasted at 1.41 Million for August Amid Stable Market Sentiment Ahead of September Release

13 sep 2026, 23:31 UTC

Upcoming U.S. Housing Starts Data Release on September 17 Expected to Influence Economic Outlook Amidst Market Fluctuations.

13 sep 2026, 23:31 UTC

U.S. Housing Starts Expected to Recover Slightly to 1.32 Million Units Amid Ongoing Concerns Over High Mortgage Rates and Recent Declines

13 sep 2026, 23:31 UTC

Philadelphia Fed Manufacturing Index Set for Release Amid Positive Sentiment and Anticipated Growth, Forecasted at 30.0

13 sep 2026, 23:31 UTC

U.S. Building Permits Data Set for Release on September 17, 2026, Amid Cautious Optimism in Housing Market Sentiment

13 sep 2026, 23:31 UTC

U.S. Retail Sales Ex Autos Expected to Rise 0.5% in August Amid Cautious Optimism on Consumer Spending

13 sep 2026, 23:31 UTC

Retail Sales MoM report for August 2026 set to release on September 16, with a forecasted increase of 0.9% amid cautious consumer spending sentiment following July's unexpected decline.

13 sep 2026, 23:31 UTC

U.S. Import Prices MoM data for August 2026 set to release on September 16, with a modest increase of 0.2% expected amid inflation concerns and potential Fed interest rate adjustments.

13 sep 2026, 23:31 UTC

U.S. Export Prices MoM Release on September 16 Expected to Impact Monetary Policy Amidst Recent Price Decline and Mixed Market Sentiment

13 sep 2026, 23:21 UTC

Macro News
News

Bitcoin is lower as U.S.-China tensions rise and crude oil prices fall. Regulatory optimism around the Bitcoin and Crypto Clarity Act fails to boost sentiment.

13 sep 2026, 23:11 UTC

EUR/NZD is trading lower during after-market hours, settling at -0.11%. The currency pair remains above its 20-day moving average.

13 sep 2026, 23:01 UTC

EUR/JPY trades higher in after-market hours, recovering from earlier lows amid expectations for a Federal Reserve interest rate hike on September 16.

13 sep 2026, 23:01 UTC

Correlated Moves

The AUD/USD is lower during after-market hours, reflecting declines in the Nasdaq 100 Index and influenced by recent consumer price index data.

13 sep 2026, 23:01 UTC

Macro News
Correlated Moves

Geopolitical tensions with China and domestic electricity concerns contribute to a decline in the Dow Jones Index, which has reached a session low below its 20-day moving average.

13 sep 2026, 23:01 UTC

Macro News
Correlated Moves

U.S.-China tensions rise over arms deals with Taiwan, impacting market sentiment. The S&P 500 Index is trading lower today, reflecting broader market weakness.

13 sep 2026, 23:01 UTC

Macro News

Geopolitical tensions are driving WTI prices higher as concerns about U.S.-China relations and Iranian pressures on Saudi Arabia impact global oil markets.

13 sep 2026, 23:01 UTC

Correlated Moves

The Russell 2000 Index is lower today, continuing a downward trend amid broader market sentiment influenced by rising core CPI data and Fed rate hike expectations.

13 sep 2026, 23:01 UTC

Correlated Moves

Platinum is trading lower, influenced by a decline in silver prices amid rising consumer inflation and expectations for a Federal Reserve interest rate hike.

13 sep 2026, 23:01 UTC

EUR/SEK is trading lower during after-market hours, reflecting a slight decline since Friday's close. The asset remains near its one-month range high.

13 sep 2026, 23:01 UTC

Correlated Moves

Silver prices are lower, influenced by gold's decline and inflation data. The asset remains below its 20-day moving average amid market pressures.

13 sep 2026, 23:01 UTC

The Nasdaq 100 Index is lower amid ongoing market weakness, following a consumer price index report that exceeded expectations and heightened rate hike speculation.

13 sep 2026, 23:01 UTC

Natural Gas is trading higher, continuing gains from Friday's close. Prices reached their highest point during the session, with no specific news identified.

13 sep 2026, 23:01 UTC

EUR/CZK is trading lower in after-market hours, reflecting a modest decline since Friday's close amid solidified market expectations for a Federal Reserve interest rate hike.

13 sep 2026, 23:01 UTC

Macro News
Correlated Moves

Gold prices are lower as market expectations grow for a Federal Reserve interest rate hike. Goldman Sachs anticipates a 25 basis-point increase at the FOMC meeting.

13 sep 2026, 23:01 UTC

Ethereum is trading lower, continuing a downward trend since Saturday's close. The asset reached a session low earlier today.

13 sep 2026, 22:51 UTC

Canada's Housing Starts Data Release on September 16 Expected to Show Continued Weakness Amid Economic Pressures

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

128.51% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 29.5 USD  128.51%

Hoogste 33 USD

Laagste 27 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat